M&T Bank
AKBA icon

M&T Bank’s Akebia Therapeutics AKBA Stock Holding History

M&T Bank’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-46,126
Closed -$627K – 1600
2020
Q2 		$627K Buy
46,126
+9,320
+25% +$96.4K ﹤0.01% 854
2020
Q1 		$279K Buy
36,806
+12,014
+48% +$93.5K ﹤0.01% 1160
2019
Q4 		$157K Buy
24,792
+6,071
+32% +$28.9K ﹤0.01% 1291
2019
Q3 		$74K Buy
18,721
+4,214
+29% +$18.1K ﹤0.01% 1515
2019
Q2 		$71K Buy
14,507
+2,894
+25% +$16.5K ﹤0.01% 1518
2019
Q1 		$96K Buy
+11,613
New +$79.7K ﹤0.01% 1489

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

M&T Bank's AKBA Position: Q3 2020 in Review

M&T Bank sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 46,126 shares — an estimated $627K sold.

M&T Bank first reported a position in AKBA in Q1 2019 and held it in 6 quarters. The position peaked at $627K in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • M&T Bank reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • M&T Bank sold 46,126 Akebia Therapeutics shares in Q3 2020, an estimated $627K.
  • M&T Bank first reported a position in Akebia Therapeutics in Q1 2019 and held it in 6 quarters.
  • M&T Bank's Akebia Therapeutics position peaked at $627K in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on M&T Bank's 13F filing for Q3 2020, filed 6 Nov 2020.